2024-11-07T11:22:06-06:00 2023-12-31 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2023-01-01 800631734 NEW YORK GENOME CENTER INC NEWY 6469777000 101 AVENUE OF THE AMERICAS 7TH FL NEW YORK NY 100131941 MARIA JOANTA CHIEF FINANCIAL OFFICER 6469777000 2024-11-06 1 0 EVAN W SEEKAMP P01907071 2127589700 2024-11-05 2023 2024-10-15 13:58:12Z TOM MANIATIS 101 AVE OF THE AMERICAS NEW YORK NY 10013 98230028 0 X WWW.NYGENOME.ORG X 2010 DE ADVANCING GENOMIC RESEARCH TO DRIVE NOVEL BIOMEDICAL DISCOVERIES TO IMPROVE HUMAN HEALTH. 24 23 224 25 1634112 0 53970524 81695780 11277968 9712534 -12410 191646 2665604 1340469 67901686 92940429 2253429 3387586 0 0 29302214 33690192 140 14225 1355909 40640090 44780821 72195873 81872824 -4294187 11067605 181740451 184052230 146891982 138136156 34848469 45916074 X OPERATE A STATE-OF-THE-ART, WORLD CLASS GENOMIC RESEARCH CENTER THAT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O. 0 0 58296070 3387586 4514112 GENOME SEQUENCING: NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST TEN YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 102,800 WHOLE GENOME SAMPLES. NYGC HAS ACQUIRED TWO OF THE NEWEST ILLUMINA NOVASEQ X SYSTEMS SEQUENCERS, EACH WITH THE CAPACITY TO SEQUENCE TWENTY THOUSAND HUMAN GENOMES ANNUALLY. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. IN ADDITION, NYGC OPERATES AN OXFORD NANOPORE PROMETHION SEQUENCER FOR LONG READ SEQUENCING, AND CONTINUED TO TEST AND VALIDATE A HIGH-THROUGHPUT SEQUENCER FROM ULTIMA GENOMICS (THE UG100). SEE SCHEDULE O. 7058489 5198422 CLINICAL SEQUENCING: NYGC IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS THROUGH ITS CLEP/CLIA CERTIFIED CLINICAL LABORATORY: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLEGENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE GENOME AND TRANSCRIPTOME SEQUENCING, CONSTITUTIONAL WHOLE EXOME SEQUENCING, TARGETED VARIANT TESTING USING SANGER SEQUENCING, ONCOLOGY WHOLE EXOME AND TRANSCRIPTOME SEQUENCING, AND THE SMASH GENOMIC ASSAY. 65354559 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 1 1 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 69 0 1 224 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 24 23 1 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AR CA CO CT FL GA HI IL KS KY LA ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X NANCY KONG 6469777154 101 AVENUE OF THE AMERICAS 7TH FL NEW YORK NY 10013 X RUSSELL L CARSON MBA DIRECTOR & CHAIRMAN 1.00 0.00 X X 0 0 0 IVAN G SEIDENBERG MBA DIRECTOR & CO-CHAIR 1.00 0.00 X X 0 0 0 HERB PARDES MD DIRECTOR & EXEC. VICE CHAI 1.00 0.00 X 0 0 0 GORDON F TOMASELLI MD DIRECTOR 1.00 0.00 X 0 0 0 BRUCE STILLMAN PHD DIRECTOR 1.00 0.00 X 0 0 0 KATRINA ARMSTRONG MD DIRECTOR 1.00 0.00 X 0 0 0 SELWYN VICKERS MD DIRECTOR 1.00 0.00 X 0 0 0 DENNIS S CHARNEY MD DIRECTOR 1.00 0.00 X 0 0 0 DAFNA BAR-SAGI PHD DIRECTOR 1.00 0.00 X 0 0 0 KEVIN J TRACEY MD DIRECTOR 1.00 0.00 X 0 0 0 KENNETH A DILL PHD DIRECTOR 1.00 0.00 X 0 0 0 RICHARD P LIFTON MD PHD DIRECTOR 1.00 0.00 X 0 0 0 ROBERT HARRINGTON MD DIRECTOR (AS OF 10/23) 1.00 0.00 X 0 0 0 FRANCIS LEE MD PHD DIRECTOR (3/23 TO 10/23) 1.00 0.00 X 0 0 0 AUGUSTINE M K CHOI MD DIRECTOR (THRU 3/23) 1.00 0.00 X 0 0 0 ELI CASDIN DIRECTOR 1.00 0.00 X 0 0 0 NICHOLAS DONOFRIO DIRECTOR 1.00 0.00 X 0 0 0 JOSEPH E EDELMAN DIRECTOR 1.00 0.00 X 0 0 0 JOHN B EHRENKRANZ DIRECTOR 1.00 0.00 X 0 0 0 ANTHONY B EVNIN PHD DIRECTOR 1.00 0.00 X 0 0 0 JOHN P HAVENS DIRECTOR 1.00 0.00 X 0 0 0 WESLIE R JANEWAY DIRECTOR 1.00 0.00 X 0 0 0 FRANK V SICA DIRECTOR & COMMITTEE CHAIR 1.00 0.00 X 0 0 0 JIM SIMONS PHD DIRECTOR 1.00 0.00 X 0 0 0 NANCY THORNBERRY DIRECTOR 1.00 0.00 X 0 0 0 TOM MANIATIS PHD SCIENTIFIC DIRECTOR & CEO 40.00 0.00 X X 659380 0 0 ELIZABETH BROOKS O'BRIEN VP & GENERAL COUNSEL 40.00 0.00 X 466101 0 44808 MARIA JOANTA CHIEF FINANCIAL OFFICER 40.00 0.00 X 385336 0 49938 CAROL ASHE CHIEF BUSINESS OFFICER 40.00 0.00 X 436587 0 19917 CHARLES GAGNON CHIEF INFORMATION OFFICER 40.00 0.00 X 344112 0 49131 THOMAS LEHNER SCI DIR, NEURO DIS GEN 40.00 0.00 X 404554 0 33760 SOREN GERMER SVP, GENOME TECHNOLOGIES 40.00 0.00 X 437568 0 37446 MICHAEL CHARLES ZODY SCIENTIFIC DIR, COMP BIOLO 40.00 0.00 X 369902 0 29110 SARAH LESSER AVINS SVP, ADVANCEMENT & CHIEF D 40.00 0.00 X 564596 0 37074 SHAILAJA GARGEYA SENIOR DIR, SOFTWARE ENGIN 40.00 0.00 X 332688 0 19917 DAYNA M OSCHWALD CHIEF OF STAFF 40.00 0.00 X 282476 0 33972 CHRISTOPHER PHIFER BLACK SENIOR DIRECTOR, RESEARCH 40.00 0.00 X 255308 0 44331 HANNAH GOULDING SENIOR DIRECTOR, HUMAN RES 40.00 0.00 X 245119 0 14824 CATHERINE E REEVES SENIOR DIRECTOR, RESEARCH 40.00 0.00 X 243210 0 32796 5426937 0 447024 98 0 1 0 DONNELLY MECHANICAL 96-59 222ND STREET QUEENS NY 11429 ENGINEERING SERVICES 928790 GUARDIAN SERVICES INDUSTRIES INC 88005 EXPEDITE WAY CHICAGO IL 60695 CLEANING SERVICES 372883 STOEKIUS RIGHTS AB MARIA PRASTGARDSGATA 28 APT 1401 STOCKHOLM SW 11852 DATA SERVICES 292688 WAYNE CLARKE 327 3D ST E SASKATOON SASKATCHEWAN CA S7H 1L4 CONSULTING SERVICES 159605 KPMG LLP PO BOX 120511 DALLAS TX 75312 ACCOUNTING SERVICES 156000 55 2735000 22283205 56677575 1358361 81695780 RESEARCH SEQUENCING 541700 5649337 4015225 1634112 CLINICAL SEQUENCING 541700 4063197 4063197 9712534 191646 191646 1575796 1575796 4415161 5289599 -874438 -874438 -874438 EDC LOAN RECOGNITION 900099 625717 625717 OTHER REVENUE 900099 13394 13394 639111 92940429 8078422 1634112 1532115 3313149 3313149 74437 74437 4369319 1971720 1795929 601670 22665670 17476751 4796175 392744 1411785 1036439 330002 45344 2705425 2105993 563114 36318 2537993 1914195 561994 61804 270206 270206 115500 115500 60069 60069 14225 14225 3317557 3009860 307697 447519 229260 208452 9807 3335668 2083854 1251706 108 522753 522753 13279549 11106579 2066932 106038 423273 356909 64021 2343 167798 101656 44581 21561 310369 193734 114552 2083 5919358 4161023 1719870 38465 752067 752067 DIRECT COST OF SEQUENCI 13033945 13030320 3625 RESEARCH 2529791 2529791 RECRUITMENT 46960 16238 30722 248439 119898 105142 23399 81872824 65354559 15162356 1355909 15599937 9326778 3505459 8022270 18649498 5451902 7382860 2260088 1607153 3583624 2491274 142750837 96679560 43861055 46071277 102961575 95017931 181740451 184052230 7934093 7098614 15840681 14803697 3380000 2660000 119737208 113573845 146891982 138136156 X 22710365 20204925 12138104 25711149 34848469 45916074 181740451 184052230 11067605 0 X 0 1 X 1 1 1 X 32878926 51639109 61556925 53970524 81695780 281741264 32878926 51639109 61556925 53970524 81695780 281741264 97345673 184395591 3205975 3312682 4952174 5045294 6808320 23324445 38049 742082 258491 19731 13394 1071747 306137456 47893123 0.60230 0.51100 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 0 0 1 70695 70695 0 PART II-B, LINE 1: THROUGH ITS LEGISLATIVE CONSULTANTS, NYGC ADVOCATES FOR GOVERNMENT FUNDS TO SUPPORT CURRENT OPERATIONS AND/OR EXPAND RESEARCH OPPORTUNITIES AT NYGC. IN 2023, NYGC ENGAGED PAID LEGISLATIVE CONSULTANTS TO REPRESENT ITS INTERESTS AT THE STATE LEVEL. ADDITONALLY, FROM TIME TO TIME, NYGC STAFF MAY CONTACT MEMBERS OF THE STATE LEGISLATURE AND EXECUTIVE BRANCH TO ENCOURAGE THEIR SUPPORT FOR NYGC. SUCH CONTACT MAY INCLUDE MEETINGS AND CORRESPONDENCE WITH PUBLIC OFFICIALS. THE APPROXIMATE COST ASSOCIATED WITH THESE ACTIVITIES IN 2023 WAS $9,003.94. NYGC ALSO MAINTAINS MEMBERSHIPS IN IRC SECTION 501(C)(6) ORGANIZATIONS THAT REPRESENT THE INTERESTS OF THE ACADEMIC MEDICAL RESEARCH COMMUNITY. IN 2023, $2,433 OF THE DUES PAID TO THESE ASSOCIATIONS WERE ATTRIBUTABLE TO LOBBYING. 0 3481000 3481000 1.00000 0 0 74702817 34209789 40493028 64620148 59227023 5393125 3427872 3242748 185124 46071277 SECURITY DEPOSITS 5516257 DEFERRED COMPENSATION 301841 OPERATING RIGHT OF USE ASSET 89199833 95017931 RIGHT OF USE LIABILITY 111520594 FINANCE LEASE OBLIGATIONS 2053251 113573845 X 98230028 0 98230028 -5289599 -5289599 92940429 87162423 5289599 5289599 81872824 0 81872824 PART V, LINE 4: THE THOMAS MANIATIS CHAIR FOR EXCELLENCE AND INNOVATION IN GENOMIC SCIENCE FUND WAS ESTABLISHED TO RECOGNIZE AND HONOR THE INTEGRAL ROLE PLAYED BY THOMAS MANIATIS, PH.D., IN MAKING THE NEW YORK GENOME CENTER A LEADER IN THE FURTHERANCE OF GENOMIC RESEARCH. A DESIGNATED PORTION, APPROXIMATELY 5% OF THE FUND'S EARNINGS ANNUALLY WILL BE MADE AVAILABLE FOR GENERAL EXPENDITURE. THE BOARD OF DIRECTORS HAS DISCRETION TO MAKE ADDITIONAL FUNDS AVAILABLE TO SUPPORT THE ESSENTIAL NEEDS OF THE ORGANIZATION. PART X, LINE 2: NYGC IS SUBJECT TO THE PROVISIONS OF THE FASB ASC SECTION 740-10-05, INCOME TAXES - OVERALL, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. NYGC RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED AND HAS DETERMINED IT DID NOT HAVE ANY EXPOSURE TO UNCERTAIN TAX POSITIONS DURING 2023 AND 2022. PART XI, LINE 4B - OTHER ADJUSTMENTS: RECLASS OF DIRECT RENTAL EXPENSE -5,289,599. PART XII, LINE 2D - OTHER ADJUSTMENTS: RECLASS OF DIRECT RENTAL EXPENSE 5,289,599. 0 EUROPE (INCLUDING ICELAND AND GREENLAND) 0 9 PROGRAM SERVICES RESEARCH 477168 NORTH AMERICA 0 3 PROGRAM SERVICES RESEARCH 252589 EAST ASIA AND THE PACIFIC 0 1 PROGRAM SERVICES RESEARCH 538 0 13 0 0 0 13 730295 0 730295 EUROPE (INCLUDING ICELAND AND GREENLAND) RESEARCH SUBAWARD 45219 WIRE 0 EUROPE (INCLUDING ICELAND AND GREENLAND) RESEARCH SUBAWARD 29218 WIRE 0 EUROPE (INCLUDING ICELAND AND GREENLAND) RESEARCH SUBAWARD 7500 WIRE 0 3 RESEARCH NORTH AMERICA 2 251450 WIRE 0 0 0 0 0 0 PART I, LINE 2: NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT. PART I, LINE 3: THE PROGRAM EXPENDITURES ARE REPORTED ON THE ACCRUAL METHOD. 1 COLUMBIA UNIVERSITY 615 WEST 131ST STREET MC841 NEW YORK NY 100277922 135598093 501(C)(3) 503374 0 RESEARCH SUBAWARD NEW YORK UNIVERSITY 70 WASHINGTON SQUARE SOUTH NEW YORK NY 10012 135562308 501(C)(3) 371367 0 RESEARCH SUBAWARD ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501(C)(3) 319946 0 RESEARCH SUBAWARD BROWN UNIVERSITY 164 ANGELL STREET BOX 1877 PROVIDENCE RI 02912 050258809 501(C)(3) 285507 0 RESEARCH SUBAWARD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 274185 0 RESEARCH SUBAWARD NYU GROSSMAN SCHOOL OF MEDICINE 550 FIRST AVENUE NEW YORK NY 10016 135562309 501(C)(3) 251210 0 RESEARCH SUBAWARD MEMORIAL SLOAN-KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 240597 0 RESEARCH SUBAWARD JOHNS HOPKINS UNIVERSITY 3400 N CHARLES STREET BALTIMORE MD 21218 520595110 501(C)(3) 197999 0 RESEARCH SUBAWARD COLD SPRING HARBOR LABORATORY 1 BUNGTOWN ROAD COLD SPRING HARBOR NY 11724 112013303 501(C)(3) 180000 0 RESEARCH SUBAWARD YALE UNIVERSITY 135 COLLEGE STREET NEW HAVEN CT 06510 060646973 501(C)(3) 179913 0 RESEARCH SUBAWARD MOREHOUSE SCHOOL OF MEDICINE INC 720 WESTVIEW DRIVE SW ATLANTA GA 303101458 581438873 501(C)(3) 95049 0 RESEARCH SUBAWARD THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 350 COMMUNITY DRIVE MANHASSET NY 11030 112673595 501(C)(3) 77917 0 RESEARCH SUBAWARD WEILL CORNELL MEDICAL COLLEGE 1300 YORK AVENUE NEW YORK NY 10065 150532082 501(C)(3) 66197 0 RESEARCH SUBAWARD REGENTS OF THE UNIVERSITY OF CALIFORNIA 1111 FRANKLIN STREET OAKLAND CA 94607 943067788 501(C)(3) 28418 0 RESEARCH SUBAWARD 14 PART I, LINE 2: NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT. 1 X X 0 0 0 0 0 0 0 0 0 TOM MANIATIS PHD SCIENTIFIC DIRECTOR & CEO 659380 0 0 0 0 0 0 0 0 0 659380 0 0 0 SARAH LESSER AVINS SVP, ADVANCEMENT & CHIEF D 564596 0 0 0 0 0 19800 0 17274 0 601670 0 0 0 ELIZABETH BROOKS O'BRIEN VP & GENERAL COUNSEL 466101 0 0 0 0 0 19800 0 25008 0 510909 0 0 0 SOREN GERMER SVP, GENOME TECHNOLOGIES 437568 0 0 0 0 0 19800 0 17646 0 475014 0 0 0 CAROL ASHE CHIEF BUSINESS OFFICER 436587 0 0 0 0 0 19800 0 117 0 456504 0 0 0 THOMAS LEHNER SCI DIR, NEURO DIS GEN 404554 0 0 0 0 0 19800 0 13960 0 438314 0 0 0 MARIA JOANTA CHIEF FINANCIAL OFFICER 385336 0 0 0 0 0 19800 0 30138 0 435274 0 0 0 MICHAEL CHARLES ZODY SCIENTIFIC DIR, COMP BIOLO 369902 0 0 0 0 0 19800 0 9310 0 399012 0 0 0 CHARLES GAGNON CHIEF INFORMATION OFFICER 339799 0 0 0 4313 0 17504 0 31627 0 393243 0 0 0 SHAILAJA GARGEYA SENIOR DIR, SOFTWARE ENGIN 322162 0 10470 0 56 0 19800 0 117 0 352605 0 0 0 DAYNA M OSCHWALD CHIEF OF STAFF 282420 0 0 0 56 0 16917 0 17055 0 316448 0 0 0 CHRISTOPHER PHIFER BLACK SENIOR DIRECTOR, RESEARCH 255308 0 0 0 0 0 15753 0 28578 0 299639 0 0 0 CATHERINE E REEVES SENIOR DIRECTOR, RESEARCH 238710 0 4500 0 0 0 15150 0 17646 0 276006 0 0 0 HANNAH GOULDING SENIOR DIRECTOR, HUMAN RES 245119 0 0 0 0 0 14707 0 117 0 259943 0 0 0 PART I, LINE 3 IN 2023, NYGC'S SCIENTIFIC DIRECTOR & CEO WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR & CEO, AN OFFICER OF THE CORPORATION AND AS A SENIOR ASSOCIATE MEMBER OF NYGC'S FACULTY. HE OVERSAW NYGC'S RESEARCH PROGRAM AND UNDERTOOK OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. THE SCIENTIFIC DIRECTOR & CEO DEVOTED 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. IN 2023, NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO PERFORM AN EXECUTIVE TOTAL COMPENSATION STUDY OF SENIOR MANAGEMENT'S COMPENSATION, INCLUDING THE SCIENTIFIC DIRECTOR & CEO. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT, INCLUDING THE SCIENTIFIC DIRECTOR & CEO, WAS REASONABLE. SILAS MANIATIS FAMILY MEMBER 180439 SALARY+BENEFITS 0 X RESEARCH SUPPLIES 103 1358361 FMV 0 0 0 FORM 990, PART I, LINE 1 & PART III, LINE 1: THE NEW YORK GENOME CENTER (NYGC) IS AN INDEPENDENT NON-PROFIT SCIENTIFIC RESEARCH INSTITUTION DEDICATED TO COLLABORATIVE GENETIC AND GENOMIC RESEARCH. NYGC'S MISSION IS TO ADVANCE GENOMIC SCIENCE, AND THROUGH ITS APPLICATION, TO DRIVE NOVEL BIOMEDICAL DISCOVERIES. NYGC'S AREAS OF FOCUS INCLUDE THE DEVELOPMENT OF COMPUTATIONAL AND EXPERIMENTAL GENOMIC METHODS AND DISEASE-FOCUSED RESEARCH TO BETTER UNDERSTAND THE GENETIC BASIS OF CANCER, NEURODEGENERATIVE DISEASE AND NEUROPSYCHIATRIC DISEASE. THE NYGC TEAM, LED BY EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO TOM MANIATIS, PHD, INCLUDES ASSOCIATE AND CORE FACULTY MEMBERS WHO HOLD JOINT APPOINTMENTS AT LEADING ACADEMIC INSTITUTIONS. THE CENTER BRINGS TOGETHER OUTSTANDING THOUGHT LEADERS FROM TEN FOUNDING & THREE ASSOCIATE MEMBER INSTITUTIONS, AND 96 AFFILIATE SCIENTIFIC MEMBERS TO ENGAGE IN COLLABORATIVE RESEARCH. CONVENING TALENT AND EXPERTISE FROM MULTIPLE TOP-TIER SCIENTIFIC AND MEDICAL INSTITUTIONS IN THE NEW YORK AREA AND BEYOND, WE HAVE CREATED A HIGHLY COLLABORATIVE SCIENTIFIC ECOSYSTEM AND COMMUNITY RESOURCE THAT IS MORE THAN THE SUM OF ITS PARTS. NYGC ALSO PROVIDES RESEARCHERS WITH ACCESS TO STATE-OF-THE-ART GENOMIC INFRASTRUCTURE (E.G., COMPUTER HARDWARE AND SOFTWARE, SEQUENCING INSTRUMENTS) AND TECHNOLOGY INNOVATION AND EXPERTISE. NYGC HAS THE FOLLOWING KEY OBJECTIVES: (I) LEADING AND CONTRIBUTING TO INTELLECTUALLY VIBRANT RESEARCH COLLABORATIONS IN THE ACADEMIC AND SCIENTIFIC COMMUNITY IN NEW YORK CITY, ACROSS THE COUNTRY AND AROUND THE WORLD. (II) RECRUITING AND RETAINING DIVERSE WORLD-CLASS SCIENTIFIC TALENT TO LEAD THE ORGANIZATION'S RESEARCH AND TECHNOLOGY DEVELOPMENT PROGRAMS; (III) SUPPORTING RESEARCH CONDUCTED BY THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH AND MEDICAL INSTITUTIONS AND THE BIOTECHNOLOGY/PHARMACEUTICAL INDUSTRY TO ADVANCE NYGC'S SCIENTIFIC RESEARCH MISSION; (IV) DEVELOPING INNOVATIVE EXPERIMENTAL AND COMPUTATIONAL GENOMIC METHODS BASED UPON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED AT THE ORGANIZATION'S FACILITY, FOR THE BROADER BENEFIT OF THE RESEARCH COMMUNITY; (V) IMPROVING HUMAN HEALTH THROUGH GENOMIC RESEARCH THAT DRIVES NOVEL BIOMEDICAL DISCOVERIES; (VI) STRIVING TO MAXIMIZE THE BENEFITS OF OUR RESEARCH AND INNOVATION FOR DIVERSE COMMUNITIES; (VII) PROVIDING TRAINING TO THE ACADEMIC, RESEARCH AND TECHNOLOGY COMMUNITIES; (VIII) CREATING A WORKPLACE ENVIRONMENT THAT IS WELCOMING AND FAIR TO ALL REGARDLESS OF RACE, ETHNICITY, GENDER, SEXUAL ORIENTATION, PHYSICAL DISABILITY, AGE, OR RELIGION, AND (IX) CONDUCTING ACTIVITIES ANCILLARY TO THESE OBJECTIVES. NYGC STRIVES TO CHAMPION DIVERSITY, EQUITY, AND INCLUSION IN ITS WORKPLACE AND IN THE APPLICATION OF ITS RESEARCH TO CLINICAL CARE. A FUNDAMENTAL GOAL OF THE GENOME CENTER IS ADDRESSING THE LACK OF DIVERSITY WITHIN DATA, SAMPLES, AND SUBJECTS IN GENOMICS RESEARCH. NYGC IS ALSO COMMITTED TO DIVERSITY ON THE CENTER'S BOARD OF DIRECTORS AND WITHIN ITS FACULTY, STAFF, AND SCIENTIFIC RESEARCHERS. FORM 990, PART III, LINE 4A & LINE 4B NEUROPSYCHIATRIC DISEASE: THE NEW YORK GENOME CENTER IS BUILDING A NEUROPSYCHIATRIC DISEASE RESEARCH PROGRAM AIMED AT INVESTIGATING THE MECHANISMS UNDERLYING NEUROPSYCHIATRIC AND NEURODEVELOPMENTAL DISORDERS, SUCH AS SCHIZOPHRENIA, BIPOLAR DISORDER, AND AUTISM SPECTRUM DISORDER. NYGC'S VISION ENCOMPASSES A MULTI-LAYERED APPROACH, INTEGRATING VARIOUS LEVELS OF ANALYSIS TO ADVANCE OUR UNDERSTANDING OF THE BIOLOGICAL UNDERPINNINGS OF NEUROPSYCHIATRIC DISORDERS. THIS INCLUDES DELINEATING THE GENETIC AND PHENOTYPIC ARCHITECTURE OF THESE DISORDERS IN DIVERSE POPULATIONS AND PERFORMING FUNCTIONAL STUDIES TO UNRAVEL THEIR UNDERLYING BIOLOGY, USING DIVERSE MODEL SYSTEMS. NYGC IN PARTNERSHIP WITH INSTITUTIONAL FOUNDING MEMBERS WILL BUILD A TRANSLATIONAL PLATFORM FOR PRECISION PSYCHIATRY DEDICATED TO PROVIDING PATIENTS WITH ACCESS TO EVIDENCE-BASED MENTAL HEALTH CARE, WITH SPECIAL EMPHASIS ON DATA SECURITY AND PATIENT PRIVACY. AN NYGC SIGNATURE PROJECT IN NEUROPSYCHIATRIC DISEASE RESEARCH IS THE GENOMIC MEDICINE FOR MENTAL HEALTH ADVANCEMENT (GEMMA) INITIATIVE, WHICH AIMS TO DEVELOP A PATIENT-CENTRIC PLATFORM FOR PRECISION PSYCHIATRY. GEMMA , A COLLABORATION BETWEEN THE NYGC, COLUMBIA UNIVERSITY, NORTHWELL HEALTH, AND THE NEW YORK STATE OFFICE OF MENTAL HEALTH WILL BE DEDICATED TO PROVIDING PATIENTS WITH ACCESS TO EVIDENCE BASED MENTAL HEALTH CARE AND THE INTEGRATION OF GENETIC AND CLINICAL RECORDS INTO PROGNOSIS, AND CLINICAL CARE. THE PLATFORM"S INITIAL TARGET POPULATION ARE THE HISTORICALLY UNDERSERVED POPULATIONS OF THE NEW YORK STATE MENTAL HEALTH SYSTEM. BEGINNING IN 2023, NYGC TOGETHER WITH THE BROAD INSTITUTE OF MIT AND HARVARD, AND THE UNIVERSITY OF CALIFORNIA, LOS ANGELES, WILL COLLABORATE TO CREATE THE BD GENETICS PLATFORM. THIS PLATFORM WILL BE USED TO PERFORM GENOMIC PROFILING OF ONE OF THE MOST DIVERSE POPULATIONS OF PEOPLE WITH BIPOLAR DISORDER, INCLUDING MORE THAN 30,000 STUDY SUBJECTS FROM AFRICA, CENTRAL AMERICA, SOUTH AMERICA, AND ASIA. ADDITIONALLY, NYGC IS ADVANCING ITS CLINICAL OUTCOME PREDICTION OF PSYCHOSIS FROM ELECTRONIC HEALTH RECORDS (COPPER), A PILOT STUDY LEVERAGING THE GEMMA PLATFORM FOCUSED ON ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING, TO BUILD MODELS OF CLINICAL PREDICTORS OF DIAGNOSIS, TREATMENT, AND PROGNOSIS OF PSYCHOSIS-RELATED DISORDERS. IN PRECISION PSYCHIATRY, THE NYGC TEAM PLANS TO INTEGRATE LARGE-SCALE LONGITUDINAL ELECTRONIC HEALTH RECORDS, DIMENSIONAL PHENOTYPING, AND GENETIC ANALYSES TO IMPROVE CLINICAL PREDICTORS OF SERIOUS MENTAL ILLNESS. BEGINNING IN 2023, DR. LEHNER AND ASSOCIATE FACULTY MEMBER, DR. TARJINDER SINGH, LAUNCHED A NEW PROJECT TO CARRY OUT WHOLE GENOME SEQUENCING AND BIOINFORMATIC ANALYSIS ON A WELL-CHARACTERIZED COHORT OF PATIENTS WITH SEVERE SCHIZOPHRENIA. IN COLLABORATION WITH DR. CARLOS PATO AT RUTGERS UNIVERSITY AND LEVERAGING NEW REDUCED-COST SEQUENCING PLATFORMS, NYGC WILL SEQUENCE AND ANALYZE A COHORT OF 2,500 PATIENTS WITH SEVERE SCHIZOPHRENIA FROM THE RUTGERS GENOMIC PSYCHIATRY COHORT TO IDENTIFY POTENTIALLY CAUSATIVE GENETIC VARIANTS. RESEARCHERS WILL ALSO BE ABLE TO USE CELL LINES DERIVED FROM EACH PARTICIPANT IN THE COHORT TO INVESTIGATE THE UNDERLYING CAUSATIVE DISEASE MECHANISMS. THE RESEARCH TEAM PLANS TO INTEGRATE THE WHOLE GENOME SEQUENCE DATA WITH EXISTING LARGE-SCALE DATASETS, CONTROLS, AND INTERNATIONAL DISCOVERY EFFORTS TO ADVANCE PRECISION MEDICINE IN PSYCHIATRY. GENOMIC TECHNOLOGY: NYGC'S TECHNOLOGY INNOVATION LAB HAS POSITIONED THE CENTER AT THE LEADING EDGE OF GENOMIC TECHNOLOGY INNOVATION, ALLOWING FOR DEEPER FUNCTIONAL STUDIES OF DISEASE BIOLOGY WITH INCREASING RESOLUTION AND BROADER ACCESSIBILITY FOR THE RESEARCH COMMUNITY. THESE INCLUDE THE DEVELOPMENT OF HIGH-THROUGHPUT TECHNOLOGIES FOR SIMULTANEOUS MEASUREMENT OF PROTEINS, RNA, AND CHROMATIN STRUCTURE AT SPATIAL RESOLUTIONS AT OR BELOW THE SINGLE CELL LEVEL, ALONG WITH SOPHISTICATED COMPUTATIONAL AND STATISTICAL TOOLS TO FURTHER THE ANALYSIS OF MULTI-MODAL GENOMICS. THE TECHNOLOGY INNOVATION LAB IS ACTIVELY INVOLVED IN ADVANCING SPATIALLY-RESOLVED SINGLE CELL TECHNOLOGIES, WHICH CAN SIMULTANEOUSLY MAP THE ACTIVITIES OF TENS OF THOUSANDS OF GENES ACROSS TISSUE SECTIONS. THE LAB PLAYED A PIVOTAL ROLE IN THE INVENTION OF SPATIAL TRANSCRIPTOMICS (ST), A GROUNDBREAKING METHOD THAT WAS NAMED METHOD OF THE YEAR IN 2020, EMPOWERING RESEARCHERS TO UNRAVEL THE COMPLEXITIES OF DISEASE GENERATION WITH UNPRECEDENTED RESOLUTION. THIS YEAR, THE TECHNOLOGY INNOVATION LAB HAS BEEN WORKING TO PUSH THE BOUNDARIES OF CURRENT ST TECHNIQUES TO ADVANCE THE TECHNOLOGY AND ITS APPLICATION. AS A RESULT, THE LAB HAS PIONEERED A NOVEL ST TECHNOLOGY EMPLOYING SIMPLE MICROFLUIDICS AND 3D PRINTABLE TOOLING TO CREATE GLASS SLIDES WITH SPATIALLY BARCODED REGIONS FOR INCREASED SPATIAL RESOLUTION, CONTINUOUS AND EFFICIENT CAPTURING, AND A LARGE FIELD OF VIEW, BROADENING THE UTILITY AND APPLICATIONS OF ST. THIS NEW METHOD MAINTAINS COST-EFFECTIVENESS AND ALLOWS FOR EASY CUSTOMIZATION ENABLING BROADER ADOPTION WITHIN THE SCIENTIFIC COMMUNITY. IN GENOMICS RESEARCH, THERE HAS ALSO BEEN A SIGNIFICANT BREAKTHROUGH AND INCREASED FOCUS ON OPTICAL MULTI-OMICS (OMO) TECHNOLOGIES THAT CAN MEASURE THE ACTIVITY OR ABUNDANCE OF RNA AND PROTEIN SIMULTANEOUSLY AND AT SINGLE-CELL RESOLUTION WITHIN INTACT TISSUES. THE TECHNOLOGY INNOVATION LAB HAS DEVELOPED AN OPEN-SOURCE CODE BASE AND CONSUMABLE DESIGN SET, TO REPURPOSE RETIRED HIGH-END DNA SEQUENCERS INTO OMO HARDWARE THAT IS EQUIVALENT TO COMMERCIAL PLATFORMS. THIS INNOVATIVE AND COST-EFFECTIVE SOLUTION ALLOWS RESEARCHERS TO GO FROM TISSUE TO ANALYZED DATA IN A MATTER OF DAYS OR EVEN HOURS, OVERCOMING FINANCIAL AND LEGAL CONSTRAINTS ASSOCIATED WITH COMMERCIAL OMO SOLUTIONS. THE TECHNOLOGY INNOVATION LAB HAS BEEN WORKING TO DEVELOP COMPANION COMPUTATIONAL APPROACHES ENABLING SPATIAL MODELING OF SUCH HIGHLY COMPLEX DATA ACROSS LARGE COHORTS OF TISSUE SAMPLES AND INDIVIDUALS, PROVIDING A COMPREHENSIVE UNDERSTANDING OF THE IMPACT OF DISEASE AND AGING ON VARIOUS ORGANS, FROM THE BRAIN TO THE LARGE INTESTINE. FORM 990, PART III, LINE 4A & LINE 4B (CONTINUED) CLINICAL LABORATORY: NYGC'S CLINICAL LABORATORY CONTINUES TO LEVERAGE ITS INFRASTRUCTURE AND EXPERTISE FOR SEVERAL LARGE-SCALE INITIATIVES IN CLINICAL GENOMICS, INCLUDING A COLLABORATION WITH WEILL CORNELL MEDICINE, NEWYORK-PRESBYTERIAN HOSPITAL ON A PRECISION MEDICINE INITIATIVE FOCUSED ON CANCER, CARDIOLOGY, ENDOCRINOLOGY, AND NEUROLOGY. THE AIM IS TO ENHANCE THE VALUE OF CLINICAL WHOLE GENOMES, RETURN CLINICALLY ACTIONABLE RESULTS, AND GAIN A DEEPER UNDERSTANDING OF THE ROLE OF GENETICS IN THERAPEUTIC RESPONSES. THE FINDINGS FROM THESE EFFORTS HAVE BEEN PRESENTED AT THE ACMG MEETING, AND NYGC PLANS TO CONTINUE UPDATING ITS PANELS TO INCORPORATE NEW GENETIC INSIGHTS ANNUALLY. THE CLINICAL LABORATORY HAS INITIATED A COLLABORATION WITH THE DEPARTMENT OF OBSTETRICS AND GYNECOLOGY AT COLUMBIA UNIVERSITY, ESTABLISHING THE WOMEN'S GENETICS CENTER (WGC). THIS CENTER LEVERAGES THE COMBINED STRENGTHS OF COLUMBIA'S MATERNAL-FETAL MEDICINE PHYSICIANS AND GENETIC COUNSELORS, ALONG WITH TNYGC'S LEADING EXPERTISE IN TECHNOLOGY AND CLINICAL GENETICS. THE WGC IS DEDICATED TO DEVELOPING AND IMPLEMENTING NOVEL CLINICAL TESTS TO IMPROVE CARE FOR PREGNANT WOMEN. TO DATE, THE CLINICAL LABORATORY HAS PERFORMED OVER 1,200 WHOLE-GENOME SEQUENCING (WGS) PRENATAL TESTS TO IDENTIFY GENETIC CAUSES OF ANOMALIES DETECTED VIA ULTRASOUND IN SUPPORT OF THIS EFFORT. ADDITIONALLY, PLANS ARE UNDERWAY TO DEVELOP MORE INNOVATIVE WHOLE-GENOME-BASED TESTS THAT WILL BENEFIT ROUTINE PRENATAL DIAGNOSIS, INCLUDING FOR NON-ANOMALOUS CASES. THESE EFFORTS AIM TO DEMONSTRATE THE VALUE OF PRENATAL GENETIC SEQUENCING (GS) FOR ANOMALIES, STILLBIRTH, AND ROUTINE PRENATAL DIAGNOSIS. THE WGC AIMS TO ESTABLISH ITSELF AS A NATIONAL AND INTERNATIONAL LEADER IN FETAL GENOMICS AND PRECISION MEDICINE BY BUILDING THE NECESSARY DATA FOR OBTAINING REIMBURSEMENT FOR CLINICAL GS TESTS. FURTHERMORE, THE WGC IS COMMITTED TO DELIVERING INNOVATIVE HEALTHCARE SOLUTIONS TAILORED TO PATIENTS OF DIVERSE RACIAL, ETHNIC, AND SOCIOECONOMIC BACKGROUNDS, ULTIMATELY DEMONSTRATING THE BROAD BENEFITS OF CLINICAL GS TO THE WIDER COMMUNITY. NYGC HAS BEEN CHOSEN AS A CLINICAL SITE FOR THE IHOPE GENETIC HEALTH INITIATIVE, A NEWLY LAUNCHED PRO BONO GENETIC TESTING PROGRAM. THIS INITIATIVE AIMS TO CREATE A GLOBAL NETWORK OF LABORATORIES AND CLINICAL SITES TO PROVIDE GENETIC TESTING FOR UNDIAGNOSED CHILDREN FROM UNDER-RESOURCED COMMUNITIES. NYGC IS ONE OF ONLY THREE SEQUENCING LABS WORLDWIDE, AND THE ONLY ONE IN THE UNITED STATES, SELECTED TO PARTICIPATE IN THE INITIAL PHASE. THANKS TO SUCCESSFUL FUNDRAISING EFFORTS AT NYGC, WE HAVE SECURED SUPPORT TO PROVIDE GENETIC TESTING FOR 85 PATIENTS THROUGH THIS PROGRAM. RESEARCH SEQUENCING: NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST TEN YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 102,800 WHOLE GENOME SAMPLES. NYGC HAS ACQUIRED TWO OF THE NEWEST ILLUMINA NOVASEQ X SYSTEMS SEQUENCERS, EACH WITH THE CAPACITY TO SEQUENCE TWENTY THOUSAND HUMAN GENOMES ANNUALLY. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. IN ADDITION, NYGC OPERATES AN OXFORD NANOPORE PROMETHION SEQUENCER FOR LONG READ SEQUENCING, AND CONTINUED TO TEST AND VALIDATE A HIGH-THROUGHPUT SEQUENCER FROM ULTIMA GENOMICS (THE UG100). NYGC'S RESEARCH SEQUENCING LAB, LED BY SOREN GERMER, PHD, SENIOR VICE PRESIDENT OF GENOME TECHNOLOGIES, PROCESSED MORE THAN 28,000 SAMPLES IN 2023, INCLUDING 4,226 WHOLE GENOME SEQUENCING SAMPLES (GERMLINE AND CANCER), AND 18,182 TRANSCRIPTOME (RNA) SEQUENCING SAMPLES. IN 2023, NYGC CONTINUED TO FOCUS ITS OPERATIONAL EFFORTS ON SINGLE CELL MULTI-OMICS, EXPANDING THE SCOPE OF APPLICATION FOR CUTTING-EDGE TECHNIQUES AVAILABLE TO THE RESEARCH COMMUNITY, INCLUDING CITE-SEQ, ECCITE-SEQ, SINGLE-NUCLEUS RNA-SEQ, DOGMA-SEQ, SINGLE-CELL LONG READ RNA AND ATAC-SEQ AND THE 10X MULTIOME ASSAY, THROUGH FUNCTIONAL GENOMIC COLLABORATIONS ACROSS MULTIPLE TISSUE TYPES AND DISEASES. THESE TECHNIQUES ALLOW SIMULTANEOUS MEASUREMENT IN THOUSANDS OF CELLS COMBINATIONS OF CELL SURFACE PROTEIN MARKERS, T-CELL AND B-CELL ANTIGEN RECEPTORS, RNA ABUNDANCE AND CHROMATIN ACCESSIBILITY INCREASING SCALE THROUGH HASHING WHICH ENABLES SAMPLE MULTIPLEXING. THE CENTER'S TECHNOLOGY DEVELOPMENT LABORATORY HAS COMPLETED SEVERAL PROJECTS IN WHICH THESE ASSAYS HAVE BEEN APPLIED SUPPORTING RESEARCH IN SCHIZOPHRENIA AND ALZHEIMER'S DISEASES FROM INDUCED PLURIPOTENT STEM DIFFERENTIATED CNS CELLS AND BRAIN TISSUE. THE LAB IS ALSO ACTIVELY SUPPORTING MULTIPLE LARGE-SCALE GRANTS INCLUDING SINGLE NUCLEUS TRANSCRIPTOME PROFILING OF POSTMORTEM SPINAL CORD OF AMYOTROPHIC LATERAL SCLEROSIS PATIENTS IN COLLABORATION WITH COLUMBIA UNIVERSITY; MULTI-OMICS MAPS OF HUMAN ENDOMETRIUM IN DIVERSE ANCESTRIES IN COLLABORATION WITH COLD SPRING HARBOR LABORATORY, NORTHWELL HEALTH AND WEILL CORNELL MEDICAL CENTER; AND THE STUDY OF THE INITIATION OF DIFFUSE AND INTESTINAL NON-CARDIA GASTRIC CANCER IN COLLABORATION WITH COLUMBIA UNIVERSITY. IN ADDITION, THE LAB CONTINUES TO SUPPORT A LARGE STUDY OF ESOPHAGEAL CANCER IN COLLABORATION WITH COLUMBIA UNIVERSITY AND CAMBRIDGE UNIVERSITY UTILIZING A NOVEL AMPLIFICATION FREE SINGLE CELL WHOLE GENOME SEQUENCING ASSAY. DIVERSITY, EQUITY, AND INCLUSION: IN 2020, NYGC LAUNCHED AN ORGANIZATION-WIDE DIVERSITY, EQUITY, AND INCLUSION ("DEI") INITIATIVE, AFFIRMING NYGC'S COMMITMENT TO TAKE ACTIONABLE STEPS TOWARD FOSTERING A COMMUNITY ENVIRONMENT THAT IS WELCOMING AND INCLUSIVE TO ALL. EACH EMPLOYEE HAS THE RIGHT TO BE TREATED WITH DIGNITY AND RESPECT OF INDIVIDUAL DIFFERENCES. IN 2023, NYGC'S CROSS-FUNCTIONAL DEI ADVISORY GROUP PROVIDED EDUCATION AND RESOURCES TO THE NYGC COMMUNITY TO RAISE AWARENESS OF DEI AND TO ENHANCE CULTURAL COMPETENCY, SUCH AS BOOK CLUBS, SHOWCASING THE WORK AND SKILLS OF A DIVERSE GROUP OF EMPLOYEES, STAFF, FACULTY AND TRAINEES, AND ORGANIZED DEI-RELATED EVENTS. THE CENTER HIRED A NEW DIRECTOR OF DEI TO SPEARHEAD EXISTING AND EXPANDED DEI EFFORTS. THE DIRECTOR LAUNCHED A DIVERSITY, EQUITY & INCLUSION IMPACT AWARD AND INITIATED PLANNING FOR AN INAUGURAL POST BACCALAUREATE EARLY CAREER DEVELOPMENT TRAINING PROGRAM. FORM 990, PART III, LINE 4A & LINE 4B THE NEW YORK GENOME CENTER (NYGC) IS COMMITTED TO ADVANCING GENOMIC SCIENCE, AND THROUGH ITS APPLICATION, TO DRIVING THE DEVELOPMENT OF NOVEL BIOMEDICAL THERAPEUTICS FOR CLINICAL CARE. RESEARCH AND FACULTY CENTRAL TO THE SUCCESS OF NYGC IS OUR TALENTED FACULTY WHO POSE FUNDAMENTAL QUESTIONS, DEVELOP NOVEL APPROACHES TO SCIENTIFIC INQUIRY, AND DEEPLY PROBE THE BIOLOGICAL MECHANISMS RELEVANT TO HUMAN HEALTH AND DISEASE. THE GENOMIC EXPERTISE OF OUR WORLD-CLASS SCIENTISTS INCLUDES CANCER, NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISEASE, GENOME EDITING, SINGLE-CELL AND SPATIALLY-RESOLVED MULTIOMICS, HIGH-RESOLUTION IMAGING, 3-DIMENSIONAL GENOME STRUCTURE, FUNCTIONAL GENOMICS, WHOLE GENOME SEQUENCING, BIOINFORMATICS, COMPUTATIONAL BIOLOGY, MACHINE LEARNING, GENOMIC DATA PRIVACY, AND MOLECULAR DIAGNOSTICS. EACH FACULTY MEMBER HAS BUILT A ROBUST RESEARCH PROGRAM AND HOLDS A JOINT TENURE-TRACK APPOINTMENT AT ONE OF OUR PARTNER INSTITUTIONS. NYGC ALSO HAS A DISTINGUISHED GROUP OF SENIOR ASSOCIATE FACULTY AND SCIENTIFIC ADVISORY BOARD (SAB) WHO ARE ESTABLISHED LEADERS IN GENOMICS AND BRING INVALUABLE SCIENTIFIC LEADERSHIP AND MENTORSHIP TO THE CENTER. OUR SENIOR LEADERSHIP TEAM, TOGETHER WITH THE EXTENSIVE EXPERIENCE AND GUIDANCE OF OUR SENIOR FACULTY AND SAB, EMPOWERS THE NEXT GENERATION OF GENOMIC RESEARCHERS TO INNOVATE AND DRIVE BREAKTHROUGHS IN BIOMEDICAL RESEARCH. IN 2023, WE EXPANDED THE EXPERTISE OF OUR ASSOCIATE FACULTY, A STRATEGIC STEP FORWARD. WITH THESE APPOINTMENTS, WE ADDED DEPTH, BREADTH, AND SCOPE TO THE GENOM\E CENTER'S OVERALL RESEARCH PROGRAM. THE NEW MEMBERS INCLUDE: STEPHAN SANDERS, PHD, BMBS, ALSO HOLDS JOINT APPOINTMENTS AS A PROFESSOR OF PEDIATRIC NEUROGENETICS IN THE DEPARTMENT OF PEDIATRICS AT THE UNIVERSITY OF OXFORD AND AS A MEMBER OF THE FACULTY AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. DR. SANDERS' RESEARCH FOCUSES ON USING GENE DISCOVERY, FUNCTIONAL GENOMICS, AND BIOINFORMATICS TO UNDERSTAND THE ETIOLOGY OF NEURODEVELOPMENTAL DISORDERS. IN ADDITION TO THEIR APPOINTMENTS AS ETHNICITY AND CANCER SCHOLARS FOR NYGC'S POLYETHNIC-1000 (P-1000) PROGRAM, ONYINYE BALOGUN, MD AND MELISSA DAVIS, PHD HAVE ACCEPTED ASSOCIATE FACULTY APPOINTMENTS AT THE GENOME CENTER. ONYINYE BALOGUN, MD HOLDS A JOINT APPOINTMENT AS ASSISTANT PROFESSOR OF RADIATION ONCOLOGY AT WEILL CORNELL MEDICINE SPECIALIZING IN THE TREATMENT OF BREAST AND GYNECOLOGIC MALIGNANCIES. DR. BALOGUN HAS CONDUCTED AND PUBLISHED BREAST CANCER RESEARCH IN NOVEL THERAPEUTICS FOR TRIPLE NEGATIVE BREAST CANCER AND BRAIN METASTASES. MELISSA DAVIS, PHD HOLDS JOINT APPOINTMENTS AS DIRECTOR OF THE INSTITUTE OF TRANSLATIONAL GENOMIC MEDICINE AND INTERIM ASSOCIATE PROFESSOR OF MICROBIOLOGY BIOCHEMISTRY AND IMMUNOLOGY AT MOREHOUSE SCHOOL OF MEDICINE (MSM) AND ASSOCIATE ADJUNCT PROFESSOR OF DEVELOPMENT AND CELL BIOLOGY, SCIENTIFIC DIRECTOR, INTERNATIONAL CENTER FOR THE STUDY OF BREAST CANCER SUBTYPES, INTERIM DIRECTOR OF HEALTH EQUITY AT THE ENGLANDER INSTITUTE OF PRECISION MEDICINE AT WEILL CORNELL MEDICINE (WCM). DR. DAVIS' RESEARCH FOCUSES ON IDENTIFYING BIOLOGICAL MECHANISMS OF RACIAL DISPARITIES IN CANCER RISK AND CLINICAL OUTCOMES OF CANCER DIAGNOSES. DR. DAVIS HAS JOINED NYGC'S MACMILLAN CSNCG AS A CO-PI, AND IS WORKING WITH NYGC AND INTERNATIONAL COLLABORATORS TO LEAD A CANCER GRAND CHALLENGES (JOINTLY FUNDED BY CANCER RESEARCH UK AND THE NIH NATIONAL CANCER INSTITUTE) PROJECT TEAM FOR SOCIETAL, ANCESTRY, MOLECULAR AND BIOLOGICAL ANALYSES OF INEQUALITIES (SAMBAI). IN 2023, NYGC SCIENTISTS PUBLISHED 69 STUDIES IN HIGH-IMPACT SCIENTIFIC JOURNALS ESTABLISHING NEW INSIGHTS INTO THE CAUSES AND MECHANISMS OF DISEASE, INNOVATIVE NEW GENOMIC TECHNOLOGIES, AND NOVEL COMPUTATIONAL APPROACHES THAT WE SHARE WIDELY WITH THE SCIENTIFIC COMMUNITY TO HELP ADVANCE PRECISION MEDICINE. AT THE CLOSE OF 2023, TWO CORE FACULTY MEMBERS, RAHUL SATIJA, PHD, AND NEVILLE SANJANA, PHD, WERE NAMED AMONG THE WORLD'S MOST CITED RESEARCHERS ON CLARIVATE ANALYTICS' 2023 HIGHLY CITED RESEARCHERS LIST FOR THE FIFTH CONSECUTIVE YEAR. THIS ANNUAL LIST GATHERS THOSE IN THE FIELD WHO DEMONSTRATED SIGNIFICANT AND BROAD INFLUENCE REFLECTED IN THEIR PUBLICATIONS OF MULTIPLE HIGHLY CITED PAPERS OVER THE LAST DECADE. THE HIGHLY CITED PAPERS RANK IN THE TOP 1% BY CITATION FOR A FIELD OR FIELDS AND PUBLICATION YEAR IN THE WEB OF SCIENCE. IN 2023, NYGC FACULTY AND SCIENTISTS WERE THE RECIPIENTS OF SEVERAL PRESTIGIOUS AND COMPETITIVE GRANTS SUPPORTING VARIOUS ASPECTS OF THE CENTER'S PIONEERING RESEARCH. SELECT AWARDS INCLUDE: THE CENTER FOR NEUROPSYCHIATRIC DISEASE, LED BY DR. THOMAS LEHNER, NYGC'S SCIENTIFIC DIRECTOR FOR NEUROPSYCHIATRIC DISEASE, RECEIVED TWO GRANTS IN SEPARATE ROUNDS OF FUNDING FROM BD: BREAKTHROUGH DISCOVERIES FOR THRIVING WITH BIPOLAR DISORDER. THE FIRST GRANT TOTALING $15M WAS AWARDED TO THE NYGC ALONG WITH THE BROAD INSTITUTE OF MIT AND HARVARD, AND THE UNIVERSITY OF CALIFORNIA, LOS ANGELES (UCLA) TO SUPPORT THE CREATION OF THE BD GENETICS PLATFORM. THIS COLLABORATIVE EFFORT WILL PERFORM GENETIC SEQUENCING ON ONE OF THE LARGEST AND MOST DIVERSE POPULATIONS OF PEOPLE WITH BIPOLAR DISORDER, INCLUDING MORE THAN 30,000 STUDY SUBJECTS FROM AFRICA, CENTRAL AMERICA, SOUTH AMERICA AND ASIA. IN COLLABORATION WITH RUTGERS UNIVERSITY AND COLUMBIA UNIVERSITY, A SECOND GRANT FROM BD WAS ANNOUNCED LATER IN THE YEAR, NAMING NYGC AS A RECIPIENT OF A THREE-YEAR $4.5M GRANT TO SUPPORT RESEARCH AIMED AT FURTHER UNDERSTANDING THE BIOLOGICAL PROCESSES UNDERLYING BIPOLAR DISORDER. THE CENTER'S COMMITMENT TO COLLABORATIVE SCIENCE WAS ALSO RECOGNIZED THROUGH A TWO-YEAR TARGET ALS GRANT AWARDED TO HEMALI PHATNANI, PHD, CORE FACULTY MEMBER AND DIRECTOR OF THE CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND) AND SANJA VICKOVIC, PHD, CORE FACULTY MEMBER AND DIRECTOR OF THE TECHNOLOGY INNOVATION LAB. THEIR MULTI-YEAR GRANT SUPPORTS THE PROJECT "CREATING A SPATIAL GENOMICS RESOURCE FOR AMYOTROPHIC LATERAL SCLEROSIS-FRONTOTEMPORAL DEMENTIA (ALS-FTD) NEUROPATHIES." THIS PROJECT WILL ADDRESS THE MOLECULAR MECHANISMS DRIVING DIVERSE ALS-FTD CAUSES. IN OCTOBER OF 2023, CHENXU ZHU, PHD, WHO HOLDS A JOINT APPOINTMENT AS AN NYGC CORE FACULTY MEMBER AND ASSISTANT PROFESSOR IN THE DEPARTMENT OF PHYSIOLOGY AND BIOPHYSICS AND THE INSTITUTE FOR COMPUTATIONAL BIOMEDICINE AT WEILL CORNELL MEDICINE, WAS AWARDED THE NATIONAL INSTITUTES OF HEALTH (NIH) DIRECTOR'S NEW INNOVATOR AWARD. DR. ZHU MARKS THE FOURTH NYGC CORE FACULTY MEMBER TO RECEIVE THE NIH DIRECTOR'S NEW INNOVATOR AWARD. NYGC IS THE RECIPIENT OF THE NIH COMMON FUND SOMATIC MOSAICISM ACROSS HUMAN TISSUES (SMAHT) NETWORK. THE AWARDED GRANTS OF $140 MILLION OVER FIVE YEARS FUND TWO RESEARCH PROJECTS LED BY SOREN GERMER, PHD, VICE PRESIDENT OF GENOME TECHNOLOGIES, SAM APARICIO, BM, BCH, PHD, FRCPATH, FRSC, SENIOR SCIENTIFIC DIRECTOR OF CANCER GENOMICS, DAN LANDAU, MD, PHD, NYGC CORE FACULTY MEMBER AND ASSOCIATE PROFESSOR OF MEDICINE IN THE DIVISION OF HEMATOLOGY AND MEDICAL ONCOLOGY AT WEILL CORNELL MEDICINE, AND RAHUL SATIJA, PHD, NYGC CORE FACULTY MEMBER AND ASSOCIATE PROFESSOR OF BIOLOGY AT NEW YORK UNIVERSITY. NYGC'S THOMAS LEHNER, PHD, MPH, GAMZE GRSOY, PHD, MIKE ZODY, PHD, CHARLES GAGNON, AND SHAILU GARGEYA RECEIVED AN AWARD FROM THE WARREN ALPERT FOUNDATION IN SUPPORT OF THE GENOMIC MEDICINE FOR MENTAL HEALTH ADVANCEMENT (GEMMA) DATA COMMONS PROJECT WHICH WILL SERVE AS A UNIQUE PLATFORM TO IMPLEMENT CLINICAL PREDICTION ALGORITHMS, THERAPEUTIC DISCOVERY EFFORTS, AND DATA-DRIVEN CLINICAL TRIAL ENROLLMENT. NYGC MADE GREAT PROGRESS IN CORE RESEARCH AREAS UNDER THE LEADERSHIP OF THE NEW YORK GENOME CENTER'S EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO, TOM MANIATIS, PHD. SELECT ACHIEVEMENTS INCLUDE: CANCER: EARLY IN 2023, NYGC LAUNCHED THE MACMILLAN CENTER FOR THE STUDY OF THE NON-CODING CANCER GENOME (CSNCG), A GROUNDBREAKING MULTI-DISCIPLINARY COLLABORATION BRINGING 23 INVESTIGATORS AND NINE INSTITUTIONS TOGETHER TO DEVELOP TECHNOLOGIES AND UNDERTAKE STUDIES AIMED AT UNDERSTANDING THE STRUCTURE AND FUNCTION OF THE NON-CODING GENOME AND EPIGENOME IN CANCER EVOLUTION, PROGRESSION, AND TREATMENT RESPONSE. THE MACMILLAN CENTER HAS A STRONG COMMITMENT TO OPEN SCIENCE AND COLLABORATION. ENABLED BY A GENEROUS LEAD GIFT FROM THE MACMILLAN FAMILY FOUNDATION, THE CSNCG HAS UNDERTAKEN THE GRAND CHALLENGE OF DECODING THE IMPACT OF THE NON-CODING GENOME IN CANCER BY CREATING AN END-TO-END DISCOVERY PLATFORM WITH EXPANSIVE RESEARCH EFFORTS, SPANNING FROM LARGE-SCALE MAPPING OF THE STRUCTURE AND FUNCTION OF DIVERSE CANCER GENOMES TO THE DEVELOPMENT OF NOVEL CELLULAR THERAPEUTICS AND DRUG DISCOVERY. THE CSNCG'S COLLABORATIVE APPROACH FOSTERS THE SHARING OF INFORMATION AND BREAKTHROUGHS WHICH POSITIONS THE CSNCG AS A CATALYST FOR TRANSFORMATIVE ADVANCEMENTS IN CANCER RESEARCH AND TREATMENT. FORM 990, PART III, LINE 4A & LINE 4B (CONTINUED) ADDITIONALLY, IN 2023, A WORLD-CLASS RESEARCH TEAM LED BY MELISSA B. DAVIS, PHD, NYGC ASSOCIATE FACULTY AND POLYETHNIC-1000 (P-1000) CANCER ETHNICITY SCHOLAR AND THE DIRECTOR OF THE INSTITUTE OF TRANSLATIONAL GENOMIC MEDICINE AT MOREHOUSE SCHOOL OF MEDICINE, WAS SELECTED AS ONE OF FIVE INTERNATIONAL RESEARCH TEAMS TO RECEIVE UP TO $25M IN FUNDING FROM CANCER GRAND CHALLENGES. WITH THESE FUNDS, THE SAMBAI (SOCIETAL, ANCESTRY, MOLECULAR, AND BIOLOGICAL ANALYSES OF INEQUALITIES) TEAM WILL ADDRESS THE ISSUE OF INEQUITIES IN CANCER PREVENTION, SCREENING, AND TREATMENT BY: FOCUSING ON PROSTATE, BREAST, AND PANCREATIC CANCERS IN DIVERSE COHORTS OF AFRICAN DESCENT FROM REGIONS WITHIN AFRICA, THE UNITED KINGDOM, AND THE UNITED STATES. BUILDING AN UNPRECEDENTED RESOURCE COMPRISED OF COMPREHENSIVE MEASUREMENTS OF SOCIAL, ENVIRONMENTAL, GENETIC, AND BIOLOGICAL FACTORS USED TO HELP DEFINE THE CAUSES OF DISPARATE OUTCOMES IN THE SELECTED POPULATIONS. THE TEAM UNITES CLINICIANS, ADVOCATES, AND SCIENTISTS ACROSS FIFTEEN INSTITUTIONS AND SEVEN COUNTRIES WITH BROAD EXPERTISE IN EPIDEMIOLOGY, EXPOSOMICS, GENOMICS, IMMUNOLOGY, AND COMPUTATIONAL BIOLOGY. DR. NICOLAS ROBINE, DIRECTOR OF COMPUTATIONAL BIOLOGY AT NYGC, AND DR. MARCIN IMIELISKI, CORE FACULTY MEMBER AT NYGC AND DIRECTOR OF CANCER GENOMICS AT NYU LANGONE HEALTH'S PERLMUTTER CANCER CENTER, ARE WORKING ALONGSIDE OTHER GENOMICS COLLABORATORS TO PROCESS AND CONTEXTUALIZE LARGE AND COMPLEX DATA USING NOVEL ALGORITHMS, CLOUD COMPUTING, AND GRAPH REPRESENTATIONS OF REFERENCE SEQUENCES, WHICH ARE WELL-SUITED TO ANALYZE GENOMIC DATA OF PARTICIPANTS FROM DIVERSE ANCESTRIES. NEURODEGENERATIVE DISEASE: THE CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND), LED BY NYGC CORE FACULTY MEMBER HEMALI PHATNANI, PHD, HAS ESTABLISHED A GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) CONSORTIUM, CONSISTING OF 42 MEMBER INSTITUTIONS WORLDWIDE. THE CGND HAS ALSO CONTRIBUTED TO ALS RESEARCH WITH THE DEVELOPMENT OF GENOMIC TECHNOLOGIES FOR THE STUDY OF RNA TRANSCRIPTION, SINGLE CELL TRANSCRIPTION, AND SPATIAL TRANSCRIPTOMICS. NYGC LEVERAGES THE SUCCESS OF OUR CGND'S FOCUS ON ALS RESEARCH TO EXTEND OUR WORK ACROSS A WIDER RANGE OF NEURODEGENERATIVE DISEASES THAT, DESPITE THEIR DIVERSE CLINICAL MANIFESTATIONS, SHARE COMMON PATHWAYS WITH ALS; SUCH DISEASES INCLUDE VASCULAR DEMENTIA, ALZHEIMER'S DISEASE, FRONTOTEMPORAL DEMENTIA (FTD), PARKINSON'S DISEASE, AND HUNTINGTON'S DISEASE. NYGC'S CGND RESEARCHERS HAVE BEEN WORKING WITH GLOBAL COLLABORATORS, UTILIZING NEW TECHNOLOGIES TO CREATE A MULTIDIMENSIONAL ATLAS OF GENE EXPRESSION IN ALS THAT PROVIDES NEW INSIGHTS INTO THE MECHANISMS THAT CONTRIBUTE TO DISEASE ONSET AND PROGRESSION. THESE BREAKTHROUGH FINDINGS ADVANCE THE UNDERSTANDING OF DISEASE MECHANISMS IN ALL NEURODEGENERATIVE DISEASES THAT SHARE COMMON PATHWAYS WITH ALS. NOTABLY, NYGC EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO, TOM MANIATIS AND NYGC CORE FACULTY MEMBER AND DIRECTOR OF THE NYGC'S CGND, HEMALI PHATNANI, HAVE BEEN WORKING CLOSELY WITH DAN DOCTOROFF AND TARGET ALS, ALONG WITH PARTNERS AT THE ALS ASSOCIATION GREATER NEW YORK CHAPTER, UNIVERSITY OF ROCHESTER MEDICAL CENTER, AND THE ELEANOR AND LOU GEHRIG ALS CENTER AT COLUMBIA UNIVERSITY TO ENCOURAGE NEW YORK STATE TO EXPAND SUPPORT FOR ALS RESEARCH IN NEW YORK. AS A RESULT OF THESE COLLABORATIVE EFFORTS, GOVERNOR HOCHUL RECENTLY ANNOUNCED A PLAN TO MAKE $25 MILLION IN STATE FUNDING AVAILABLE FOR ALS RESEARCH AND CARE - FUELING EARLY DIAGNOSIS EFFORTS, SCIENTIFIC STUDIES, AND DRUG DEVELOPMENT, AND PAVING THE WAY FOR MAJOR RESEARCH EFFORTS IN ALS, NEURODEGENERATIVE DISEASE, AND AGING IN NEW YORK STATE. FORM 990, PART VI, SECTION A, LINE 2 NYGC BOARD MEMBERS ELI CASDIN, ANTHONY EVNIN, THOMAS MANIATIS, JAMES SIMONS, AND NANCY THORNBERRY HAVE A BUSINESS RELATIONSHIP, EITHER DIRECTLY OR INDIRECTLY, THROUGH KALLYOPE, INC., A BIOTECHNOLOGY COMPANY DEVELOPING ORAL THERAPEUTICS AGAINST METABOLIC, NEUROLOGICAL, AND GASTROINTESTINAL DISEASES. NYGC HAS NOT CONDUCTED ANY BUSINESS WITH KALLYOPE, INC. FORM 990, PART VI, SECTION A, LINE 6 ORGANIZATION MEMBERS AS OF DECEMBER 31, 2023, THE CENTER HAD A TOTAL OF 13 MEMBERS, CONSISTING OF TEN INSTITUTIONAL FOUNDING MEMBERS AND THREE ASSOCIATE MEMBERS. THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) MEMORIAL SLOAN-KETTERING CANCER CENTER, (4) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (5) NEW YORK-PRESBYTERIAN HOSPITAL, (6) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (7) NORTHWELL HEALTH, (8) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (9) THE ROCKEFELLER UNIVERSITY, AND (10) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK. ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, AND (3) HACKENSACK MERIDIAN HEALTH. FORM 990, PART VI, SECTION A, LINE 7A ORGANIZATION MEMBERS - DECISION MAKING EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGC'S BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR/CEO AND INDEPENDENT DIRECTORS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS AND HAS THE DISCRETION TO MAKE CERTAIN DECISIONS WITHOUT FORMAL BOARD APPROVAL FORM 990, PART VI, SECTION B, LINE 11B FORM 990 REVIEW THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE CHIEF FINANCIAL OFFICER; DIRECTOR OF FINANCE; GENERAL COUNSEL; AND THE SCIENTIFIC DIRECTOR/CEO REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE OF THE BOARD FOR REVIEW AND COMMENT. ALSO PRIOR TO FILING, MANAGEMENT PROVIDES THE FORM 990 TO THE ENTIRE BOARD OF DIRECTORS FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY & REVIEW NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, OFFICERS, AND KEY EMPLOYEES) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST DISCLOSED BY BOARD MEMBERS OR OFFICERS MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY PRESENT INFORMATION RELEVANT TO THE CONFLICT OF INTEREST OR UNDERLYING TRANSACTION AT A BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION REVIEW AND APPROVAL FFOR THE ORGANIZATION'S TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR THE PROCESS OF DETERMINING COMPENSATION. FOR 2023, NYGC HIRED AN INDEPENDENT, OUTSIDE COMPENSATION CONSULTANT TO PERFORM AN ANALYSIS OF SENIOR MANAGEMENT'S TOTAL COMPENSATION. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO MEMBERS OF SENIOR MANAGEMENT WAS REASONABLE. THE COMPENSATION COMMITTEE OF THE BOARD (WHICH IS COMPOSED OF INDEPENDENT BOARD MEMBERS) MET AT A COMMITTEE MEETING HELD IN JANUARY 2023 AND APPROVED THE 2023 COMPENSATION TO BE PAID TO SENIOR MANAGEMENT. THE COMMITTEE DOCUMENTED ITS ACTIONS IN WRITTEN MEETING MINUTES. THE SENIOR MANAGEMENT TEAM RECEIVED STANDARD MERIT INCREASES IN 2023. MARIA JOANTA RECEIVED A SALARY INCREASE IN 2023 TO BRING HER SALARY CLOSER TO MARKET LEVELS AT THE RECOMMENDATION OF AN INDEPENDENT COMPENSATION CONSULTANT WHO PERFORMED AN EXECUTIVE TOTAL COMPENSATION STUDY FOR NYGC. THIS SALARY CHANGE WAS REVIEWED BY A COMPENSATION COMMITTEE OF INDEPENDENT BOARD MEMBERS AND APPROVED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION C, LINE 19 NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART VII, SECTION A IN 2023, TOM MANIATIS, PHD., SCIENTIFIC DIRECTOR & CEO, WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR AND CEO, AN OFFICER OF THE CORPORATION, AND AN ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAMS AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. DR. MANIATIS DEVOTES 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS.